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Abstract
Osteogenesis imperfecta (OI), is a heterogeneous group of inherited disorders of connective tissue characterized 
by bone fragility. Patients with this disease frequently suffer fractures, over 80% of the extremities due to the 
more intensive mechanical load. Fractures of the facial bones occur very infrequently. Several studies have proved 
that bisphosphonate therapy may be effective in reducing fracture risk in OI patients. We report here an unusual 
case of pathological mandibular fracture following simple molar extraction in an adult patient with OI type I and 
oral alendronic acid treatment. Extraction was atraumatical and without bone removal . Fracture was treated by 
internal fixation by plate osteosynthesis and additional mandibulomaxillary fixation (MMF). Bone healing after 
fracture treatment was completely normal and no clinical signs of osteoneocrosis were observed. To the best of 
our knowledge, this is an unusual complication even in this type of patients. Particular care is necessary is these 
patients during oral surgery, even when they have been treated and controlled. 
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Introduction
Osteogenesis imperfecta (OI), also known as “brittle 
bone” disease, is a heterogeneous group of both domi-
nantly and recessively inherited disorders of connec-
tive tissue characterized by bone fragility (1). Due in 
most cases to a mutation in the genes responsible for 
the production of procollagen, the osteoblast produces 
an abnormal matrix that does not respond adequately to 
mechanical loads (2). Its overall incidence is approxi-
mately one in 10,000 births (1,2). Patients with OI fre-
quently suffer fractures, either caused by relatively mild 
trauma or occurring spontaneously. This is encountered 
in up to over 80% of the extremities due to the more 
intensive mechanical load. Fractures of the facial bones 
occur very infrequently (3).
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There is currently no cure for OI and treatment strate-
gies are essentially palliative and designed to improve 
quality of life. Over the past decade several studies 
have shown that bisphosphonate therapy is effective in 
reducing fracture risk and decreasing bone pain in OI 
patients (4-6). The hypothesis initially underlying their 
use in an osteoblast disorder such as OI was that a de-
crease in bone-resorbing activity might compensate for 
the weakness of the bone-forming cells and reduce the 
osteoporosis induced by lack of use (6).
We report a case of pathological mandibular fracture 
following simple molar extraction in an adult patient 
with OI type I and oral bisphosphonate treatment. To 
the best of our knowledge, this is an unusual compli-
cation even in this type of patients. Bone healing after 
fracture treatment was completely normal and no clini-
cal signs of osteoneocrosis were observed. 
Case Report
In November 2008, a 31-year-old man was referred by 
his dentist to the Department of Oral and Maxillofacial 
Surgery at the University Central Hospital (Oviedo, 
Spain) because of severe pain and swelling of the left 
mandibular body after left first molar extraction one 
day earlier. Medical history revealed that the patient 
had been diagnosed with type I OI according to the Sil-
lence et al. (7) classification. The diagnosis was based 
on the history of lower and upper extremity fractures, 
blue sclera and low bone density. 
The patient had undergone weekly therapy with 70 mg 
of oral alendronic acid from March 2000 to August 
2006. In February 2008, bisphosphonate therapy was 
reintroduced due to a decreased bone mineral density 
(BMD). Lumbar spine and femoral neck BMDs before 
dental extraction were 0.724 and 0.959 gr/cm2, respec-
tively. C-terminal telopeptide (CTX) value was 50 pg/
mL.
As referred by the patient, extraction was atraumatical 
and without bone removal. A cracking noise associated 
with a sudden painful sensation was noted intraopera-
tively. Clinical examination showed extraoral swelling 
of the left mandibular area. A panoramic radiograph 
(Fig. 1) and computed tomography (CT) revealed a frac-
ture with atypical angular course in the left body of the 
mandible, not dislocated (Fig. 2 and 3). A pathological 
fracture was diagnosed. 
An open reduction, internal fixation by plate osteo-
synthesis and additional mandibulomaxillary fixation 
(MMF) were performed under general anaesthesia. 
On postoperative day 15, MMF was released. Soft diet 
was prescribed for one month. The patient showed un-
eventful bone healing following treatment. No signs of 
osteonecrosis or nonunion were observed after seven 
months of follow-up. 
Fig. 1. A.- Panoramic radiograph showing an atypical an-
gular course of the pathological mandibular fracture.
Fig. 3. CT image revealing a pathological fracture in relation with 
the left first molar alveolar socket. 
Fig. 2. 3D reconstruction of the CT confirmed the presence of a 
non dislocated fracture in the left body of the mandible.
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Discussion
OI, a heritable disorder of bone formation, is charac-
terized by bone fragility and low bone mass. The most 
common classification of this pathology was presented 
by Sillence et al. (7) and subdivides patients into four 
types based on disease severity and progression. Type 
I OI, the most common form of the disease, is non-
deforming and results in patients attaining close to a 
normal height. Fractures are rarely observed at birth, 
but begin with ambulation and subsequent falls during 
juvenile development, then commonly decrease fol-
lowing puberty. Vertebral and long bones fractures are 
common, but mandibular or facial fractures are rarely 
described (1,2,7). 
Physiotherapy, rehabilitation and orthopaedic surgery 
are the mainstay of treatment in OI (8). Several medical 
therapies such as the use of calcitonin, sodium fluoride, 
growth hormone, cortisone and vitamins C and D have 
proven ineffective (2). However, cyclical intravenous 
treatment with pamidronate has a beneficial effect in 
children and adolescents with severe OI, and is now 
used worldwide to treat children and adolescents with 
moderate to severe forms of OI (4). Bisphosphonates ap-
pear to interfere with osteoclast activity through several 
mechanisms such as preventing osteoclast formation, 
inhibiting osteoclast activity, and causing early osteo-
clast apoptosis (9). The decreased osteoclast activity 
results in the therapeutic benefit of a reduction in bone 
pain, increased cortical bone thickness, and increased 
bone strengt (10). In 2003, an observational trial dem-
onstrated that oral alendronate increased lumbar spine 
BMD and a decreased number of fractures in 15 chil-
dren with OI (10). It is currently unknown significant 
differences between oral and intravenous bisphospho-
nate therapy in OI patients (11). 
In recent years, bisphosphonate-related osteonecrosis of 
the jaws (BRONJ) was reported in a wide number of pa-
tients receiving bisphosphonates (12,13). Otherwise, so 
far there has not been any report of BRONJ in patients 
affected by OI with high exposition to bisphosphonates, 
even after oral surgery (14,15). This factor may place 
this group of patients at a lower risk of developing bone 
osteonecrosis. However, until more information is col-
lected, it is recommended that before the start and dur-
ing bisphosphonate therapy the patients be referred to a 
dentist for examination and follow-up.
A pathological mandibular fracture following simple 
molar removal is a rare complication. Pathologic frac-
tures are complex to treat because of their diverse aeti-
ologies and the impact these will have in relation to 
normal bone healing. A patient with OI may simply ex-
perience increased fracture risk when exposed to suffi-
cient trauma (1,2). In comparison with healthy patients, 
fractures heal more rapidly but the newly formed bone 
is of the same inferior quality as the original one. More-
over, some reports suggest that there is no influence of 
bisphosphonate treatment on fracture healing, whereas 
others show a delay of fracture healing in animal mod-
els (16). 
In conclusion, particular care is necessary is these pa-
tients during oral surgery, even when they have been 
treated and controlled. Bisphosphonate treatment im-
proves BMD, but risk of BRONJ and complications in 
fracture healing are present in these patients. 
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